AD/PD 2021 | Gamma sensory stimulation for the treatment of AD

Li-Huei Tsai, PhD, Massachusetts Institute of Technology, Cambridge, MA, provides an overview of novel research into the use of non-invasive sensory stimulation for the treatment of Alzheimer’s disease (AD). In preclinical mouse models of AD, it has been demonstrated that the use of light and sound stimulation of 40Hz gamma brain rhythms, which play a role in high order cognition, results in a significant reduction in amyloid and tau protein accumulation, as well as improvements in cognition and memory. The technique, known as Gamma ENtrainment Using Sensory Stimuli (GENUS), has recently been investigated in a Phase IIa study (NCT04055376) in patients with early-stage AD which demonstrated beneficial effects following 3 months of treatment. This interview took place during the AD/PD™ 2021 conference.